Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disorder globally ( The pathophysiology of MASLD is multifactorial and closely linked to obesity, metabolic syndrome, insulin resistance, and type 2 diabetes mellitus (T2DM) ( Currently, managing MASLD remains a major clinical challenge, as no pharmacological agents have been specifically approved for its treatment
Lancet 390 (10113), 26272642
A phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study of AMG 133 in subjects with obesity: late breaking: a phase 1 study of AMG 133 in subjects with obesity
The most commonly cited starting protocol in the medical literature and clinical practice involves 250 micrograms administered once daily for acute injury, stepping up to 500 micrograms daily if response is insufficient after one to two weeks
US$ 23.11
US$ 29.38
US$ 24.88
US$ 28.62
US$ 20.25
US$ 28.90
US$ 29.39
US$ 26.21
US$ 25.67
US$ 28.87
US$ 27.29
